Upload
others
View
3
Download
0
Embed Size (px)
Citation preview
Exactech Investor Update
Helping surgeons worldwide make patients more mobile
Q1 • 2017
Investment Highlights
Targeting $47 billion
global biomedical device
market
Consistent long term
growth2x as fast as overall
market
Broad product portfolio
of innovative products
Robust product pipeline
expanding company’s
market
Highly experienced
orthopaedic management
team
Growing sales
organizationwith increasing rep
productivity
Proven track recordof creating long-term
profitable growth
2
Our Strategy
CUSTOMER INTIMACY
Innovation Channel
Development
Operational Excellence
3
Our Story
Surgeon founded Innovation to improve
patient outcomes
Surgeon input driven Collaborative relationship
with
sales force
Financial stability
4
A proven track record of growth
5
1985 1990 1994 1998 2002 2006 2010 2014 2017
$268M
First Knee Implant Sales
1994
Launched Internal Manufacturing
1998
Equinoxe® Shoulder Launch2
00
5
French Distributor Acquisition
2008
Vertical Supply Acquisitions
2010
Launching Vantage Ankle
& Truliant Knee Systems2017
Launched Three
Revision Systems2016
Launch of ExactechGPS®
CAS Technology Acquisition2014
250
200
150
100
50
0
RE
VE
NU
E I
N M
ILL
ION
S
YEAR
Source: OrthoWorld Orthopaedic Industry Annual Report April 2016 and company estimates
Targeting Highly Attractive Markets
Hip
2% Growth Rate
$7.0 BillionSales
6
Knee
4% Growth Rate
$8.5 BillionSales
Biologics
3% Growth Rate
$4.9 BillionSales
Extremities
8% Growth Rate
$2.0 BillionSales
ExactechGPS® KNEE HIP
EXTREMITIES ANKLE CEMENT/SPACERS
BIOLOGICS
2016 sales by segment based on 2016 SEC 10-K excluding divested spine business
2016 Sales by Segment ($ millions)
Broad Portfolio of Innovative Products
40%
11%
30%
19%
OTHER
$27.8
EXTREMITIES
$100.3HIP
$46.7
KNEE
$76.2
7
Equinoxe® Platform Shoulder
redefining intra-operative
flexibility, solving clinical
challenges surgeons face.
Extremities
Primary, Fracture, Reverse
Bone conserving glenoid options
Revision, Salvage and Tumor
solutions
Pipeline of strong clinical publications
ExactechGPS® Computer Assisted
Surgery System launching 2H17
Preserve Short Stem launching 2H17
8
VantageTM Ankle System
Developed by world-class team of
design surgeons. Full launch in 2017.
Extremities
9
Comprehensive total knee system
with excellent clinical results.
Knee
40-year evolved design
Multiple constraint options for primary &
revision knees with NCM poly
Exactech GPS® - Computer Assisted
Surgery System
Optetrak Logic® CC revision
10
Truliant® high performance, comprehensive system addresses primary and revision knee replacement.
Knee
Supports surgeon goals for reproducible
clinical outcomes
Wide array of options for improved
versatility
Modified implant design to accommodate
various patient anatomy
Intuitive instrumentation with visual,
audible and tactile feedback for
intraoperative adjustability
Expanded Exactech GPS® computer-
assisted surgery applications
Clinical introduction in 2H17 11
Primary, Fracture, Revision
Tapered Wedge and Neck Preserving Stem designs
Direct Anterior Approach instrumentation
Acetabular cup with InteGrip® technology
Alteon® Monobloc Revision System
HipAddressing the major
philosophies of THA
12
Surgeon maintains operating control
Reproducible outcomes - Real-time feedback
Competitive marketing edge for hospitals
Applications for shoulder, primary and revision knee
ExactechGPS®
Surgeon controlled, computer-assisted technology for reproducibility in total joint arthroplasty.
13
Innovative, clinically effective
biomaterials
Biologics
Optecure® Allograft DBM products
Accelerate® Cell Therapy
OssilixTM Calcium Phosphate Cement
ReveilleTM Cartilage Processor
14
Safety, simplicity and efficacy
Cement, Spacer
and Implant
Removal
Cemex® bone cement
InterSpace® preformed hip, knee and
shoulder spacers with High Release
technology
AcuDriver® Automated Osteotome
System
15
Exactech Manufacturing
Manufacturing
in U.S.
65% Internal
Implant Mfg
Lean initiatives in
manufacturing and
entire company.
16
GLOBAL
OFFICES/SUBSIDIARIES
DISTRIBUTORSMANUFACTURING &
HEADQUARTERS
Our Reach
US
Network of independent sales agencies (35+)
Independent sales representatives (300+)
Managed by corporate regional vice presidents
OUS
Network of independent distributors and wholly-owned subsidiaries
Direct operations in: UK, Spain, Germany, France, Japan, China, Australia
17
Financial Trends
224
237
248242
257
268
160
220
280
12 13 14 15 16 17G
Revenues ($ Mil)
FY Guidance $264-272MM; +6-9% Proforma*
0.96
1.12
1.18
1.04
1.18
1.28
0.80
1.00
1.20
1.40
12 13 14 15 16* 17G
Earnings Per Share
FY’17 Guidance $1.24-1.32
* Non-GAAP Revenue Growth and Diluted EPS Estimates excluding impact of
impairment/restructuring announced 4Q16
18
Summary Financial Data
$ and shares in millions Dec-16 Mar-17
Cash $13.1 $11.2
Debt $20.0 $16.0
Shareholders’ Equity $234.2 $240.3
Common Shares Outstanding (1) 14.3
Market Value (2) $433.4
19
(1) Per 5.3.17 1Q17 10-Q filing
(2) Based on Market Closing Price $30.20 5.9.17
Why Exactech?
Understanding of market needs and
opportunities
Major new product introductions
Sales channel opportunities
Proven financial performance and
corporate stability
20
Thank you.
This presentation contains various forward looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 21E ofthe Securities Exchange Act of 1934 which represent the company’s expectations or beliefs concerning future events. These forward lookingstatements are further qualified by important factors that could cause actual results to differ materially from those in the forward lookingstatements. These factors include the effect of competitive pricing, the company’s dependence on the ability of third party manufacturers to producecomponents on a basis which is cost-effective to the company, market acceptance of the company’s products and the effects of governmentregulation, including without limitation an ongoing investigation by the U.S. Department of Justice of various practices within the orthopaedicindustry, as well as other risks and uncertainties including those described in the company’s filings with the Securities and Exchange Commission.You should carefully consider these risks before making a decision to invest in our securities. Results actually achieved may differ materially fromexpected results included in these statements.